Ruth Schmid leads the totally renewed Executive Board of the ETPN!

Ruth Schmid , VP Marketing at SINTEF, has been elected new chairperson of the ETP Nanomedicine Executive Board during the General Assembly held on June 17th 2019 on the fist day of the Nanomed Europe 2019 event (NME19) in Braga, Portugal. She will lead the platform with the support of a brilliant and entirely renewed team, with notably Agnès Pottier (Head of Discovery at Nanobiotix) and Raymond Schiffelers (Professor in Nanomedicine at UMC Utrecht) as vice chairpersons. Meet the new ETPN ExBo!

Discover the new ETPN ExBo

Join us at Nanomed Europe 2019 #NME19 on June 17-19 in Braga, Portugal

Nanomed Europe 2019 (www.nme19.eu) #NME19 is a new and unique conference for scientists, entrepreneurs, industry and clinicians, developing great medical applications based on nanotechnology and emerging MedTech. NME19 is co-organized by the ETPN, European Technology Platform on Nanomedicine and INL, the International Iberian Nanotechnology Laboratory. Abstract submission open until April 15th! Early-bird registration fees available until April, 1st.

Know more

What is nanomedicine?

Nanomedicine is the application of nanotechnology to achieve innovation in healthcare. It uses the properties developed by a material at its nanometric scale 10-9 m which often differ in terms of physics, chemistry or biology from the same material at a bigger scale.

Moreover, the nanometric size is also the scale of many biological mechanisms in the human body allowing nanoparticles and nanomaterials to potentially cross natural barriers to access new sites of delivery and to interact with DNA or small proteins at different levels, in blood or within organs, tissues or cells.

Know more

ETPN strategic inputs

As a major pan-European industry-oriented initiative, the ETPN aims at strengthening Europe’s capabilities and competitiveness in the area of nanomedicine innovation. Since 2005 the ETPN published a number of strategic documents outlining the needs and roadmaps for nanomedicine research in Europe.

We have contributed to set up numerous European funded projects providing a first impression of the conditions for a suitable social and economic environment and the structural requirements for an efficient translation of R&D results into innovative nanomedicine.

Know more

ETPN support to innovation

Complementary to its strategic inputs as an ETP to shape and support public funding on the most promising areas of Nanomedicine, the ETPN has designed in 2014 unique technical infrastructures regrouped in a central instrument: the Nanomedicine Translation HUB.

These free of charge services support and accelerate the development of the best Nanomedicine projects from innovative design to clinical development.

Know more

Key reasons to become a member:

Meet new partners and end-users
Share your success stories
Benefit from unique advantages
Shape the future of Nanomedicine in europe
Promote and educate

Know more

Are you on the Nanomedicine map?

The NanoMed Map provides thorough insights into the nanomedicine community by showing all the actors of the ecosystem in Europe and beyond. It was initiated by NanoMed 2020, CSA project under FP7_Health.

See the map



Latest news

“The solid progress of nanomedicine” new article in Drug Delivery & Translational Reserach

Mar 6, 2020

The end of the hype of #nanomedicine? Well... let's talk about facts: 50 marketed nanomedicine, 100+ in clinical trials. Unique features, notably for smarter #drugdelivery of multiple drugs at the same time, delivery of fragile molecules like #RNA, etc. Read the new...

New publication of the JRC about the definition of nanomaterials by the European Commission

Mar 5, 2020

The JRC of the European Commission has recently published a report providing recommendations for a harmonised and coherent implementation of the nanomaterial definition in any specific regulatory context at European Union and national level. It addresses its key...